Exhibit 10.1 SETTLEMENT AND LICENSE AGREEMENT This Agreement is made effective (the "Effective Date") the 25th day of November, 2009. BETWEEN: VERIFYSMART CORP., and for and on behalf of its affiliates, with its address for notices hereunder at Fort...Settlement and License Agreement • December 4th, 2009 • Verify Smart Corp. • Metal mining • London
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks • California
This Settlement and License Agreement (“Agreement”) made and entered into as of June 21, 2021 (the “Effective Date”), by and between, on the one hand Medytox, Inc. (“Medytox”) a company duly organized and existing under the laws of South Korea, having its principal office at 78 Gangni 1-gil Ochang-up Cheongwon-gu Cheongju-si North Chungcheong 28126, Republic of South Korea, and, on the other hand, AEON Biopharma, Inc., (“AEON”) a company duly organized and existing under the laws of Delaware, having its principal office at 4040 MacArthur Boulevard, Suite 260, Newport Beach, CA 92660 (each individually a “Party,” and collectively the “Parties”).
Biogen Swiss Manufacturing GmbH Biogen International Holding Ltd. c/o Biogen Inc.Settlement and License Agreement • June 7th, 2023 • New York
We refer to the proposed Settlement and License Agreement attached hereto as Exhibit A to be entered into by Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and each of the parties listed on Appendix I thereto, to be dated as of the date of this letter agreement (the “License Agreement”). Capitalized terms used and not defined in this letter agreement (the “Agreement”) shall have the meaning ascribed in the License Agreement.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • May 5th, 2010 • Opti Inc • Semiconductors & related devices
THIS SETTLEMENT AND LICENSE AGREEMENT (hereinafter “Agreement”) is made the 30th day of April, 2010, by and between OPTi INC. (hereinafter “OPTi”) a corporation organized and existing under the laws of the State of California, and ADVANCED MICRO DEVICES, INC. (hereinafter “AMD”), a corporation organized and existing under the laws of the State of Delaware.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • May 8th, 2012 • Santarus Inc • Pharmaceutical preparations • California
This action for alleged patent infringement (the “Litigation”) has been brought by Plaintiff Depomed, Inc. (“Depomed”) against Defendants Lupin Pharmaceuticals, Inc. and Lupin Limited (collectively, “Lupin”) for alleged infringement of United States Patent Nos. 6,635,280, 6,340,475, and 6,488,962 (collectively the “Depomed Patents”). Depomed’s commencement of the Litigation was based on its receipt of notice from Lupin Limited that Lupin Limited had filed Abbreviated New Drug Application (“ANDA”) No. 91-664 with the United States Food and Drug Administration containing a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) directed to the Depomed Patents and seeking approval to market 500 mg and 1000 mg metformin tablets as a generic version of Glumetza®.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • April 23rd, 2016 • Delaware
This Settlement and License Agreement (this “Agreement”) is entered into by and between Endo Pharmaceuticals Inc. (“Endo”), Teikoku Pharma USA, Inc. (“TPU”), Teikoku Seiyaku Co., Ltd. (“Teikoku Seiyaku,” and together with TPU, “Teikoku”, and collectively with Endo, “Endo/Teikoku”), on the one hand, and Watson Laboratories, Inc. (“Watson”), on the other hand. Endo, TPU, Teikoku Seiyaku and Watson are individually referred to herein by name or the term “Party” and are referred to collectively herein as the “Parties.” This Agreement is entered into on and is effective as of May 28, 2012 (the “Effective Date”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • September 4th, 2015 • Enzo Biochem Inc • Services-medical laboratories • New York
This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of July 20, 2015 (the “Effective Date”) by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 (“Enzo”), and Defendant Siemens Healthcare Diagnostics Inc., a corporation organized and existing under the laws of the State of California, having offices at 511 Benedict Ave., Tarrytown, NY 10591 (“Siemens”). Enzo and Siemens are individually referred to herein as a “Party,” and collectively as the “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • July 31st, 2018 • Immersion Corp • Computer peripheral equipment, nec • Delaware
This Settlement and License Agreement (“Agreement”) is made as of January 26, 2018 (“Effective Date”) between Apple Inc., a California corporation (“Apple”) and Immersion Corporation, a Delaware corporation (“Immersion”). As used herein, “Party” refers to either Immersion or Apple, and “Parties” refers to Immersion and Apple collectively.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • March 9th, 2011 • Opti Inc • Semiconductors & related devices • California
This Settlement and License Agreement (“Agreement”) is made as of December 6, 2010 (“Effective Date”) between Apple Inc., a California corporation (“Apple”) and OPTi Inc., a California corporation (“OPTi”). As used herein, “Party” refers to either OPTi or Apple, and “Parties” refers to OPTi and Apple collectively.
Settlement and License AgreementSettlement and License Agreement • June 23rd, 2017 • Kala Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Settlement and License Agreement (including its attachments, this “Agreement”) is entered into as of October 24, 2014 (“Settlement Agreement Effective Date”), by and between GrayBug, LLC, a limited liability company organized and existing under the laws of the State of Maryland and having an address of P.O. Box 13043, Baltimore, MD 21203, on behalf of itself and its Affiliates (as defined below) (collectively, “GrayBug”), and Kala Pharmaceuticals, Inc., a corporation organized and existing under the laws of State of Delaware and having a place of business at 100 Beaver Street, Suite 201, Waltham, MA 02453, on behalf of itself and its Affiliates (collectively, “Kala”).
RECITALSSettlement and License Agreement • October 27th, 2004 • Corixa Corp • Biological products, (no disgnostic substances) • California
SETTLEMENT AND LICENSE AGREEMENT AND MUTUAL GENERAL RELEASESettlement and License Agreement • November 6th, 2006 • Trizetto Group Inc • Services-computer processing & data preparation • California
This Settlement and License Agreement and Mutual General Release (the “Agreement”) is made and entered into by and between MCKESSON INFORMATION SOLUTIONS LLC (“McKesson”), a Delaware Corporation with its principal offices at 5995 Windward Parkway, Alpharetta, Georgia 30005, and THE TRIZETTO GROUP, INC. (“TriZetto”), a Delaware corporation with its principal offices at 567 San Nicolas Drive, Suite 360, Newport Beach, California 92660. The Agreement is effective as of the date last executed by the parties as set forth next to its signature below, whichever date is later (the “Effective Date”). Where appropriate, McKesson and TriZetto are collectively referred to herein as the “Parties.”
AGREEMENT RELEVANT TO THE SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • September 27th, 2010 • Trimeris Inc • Biological products, (no disgnostic substances)
This AGREEMENT RELEVANT TO THE SETTLEMENT AND LICENSE AGREEMENT (“Relevant Agreement”) is made this 23rd day of September, 2010 (“Relevant Agreement Effective Date”) by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (the latter two companies collectively, “Roche”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • November 8th, 2006 • Cephalon Inc • Pharmaceutical preparations • Delaware
THIS SETTLEMENT AND LICENSE AGREEMENT (“Agreement”) is entered into effective as of the 2nd day of August, 2006 (“Effective Date”), by and between CEPHALON, INC., a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 41 Moores Road, Frazer, Pennsylvania (“Cephalon”), CARLSBAD TECHNOLOGY, INC., a corporation organized and existing under the laws of the State of California, with its principal place of business at 5923 Balfour Court, Carlsbad, California (“Carlsbad”), and WATSON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Nevada, with its principal place of business at 311 Bonnie Circle, Corona, California (“Watson”). Each of Cephalon, Carlsbad and Watson are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
EXHIBIT 10(s) SETTLEMENT AND LICENSE AGREEMENT This Settlement and License Agreement (the "Agreement") is entered into as of the Effective Date defined below in paragraph 1.2, by (i) ENZO LIFE SCIENCES, INC. ("LIFE SCIENCES") and ENZO BIOCHEM, INC....Settlement and License Agreement • October 14th, 2004 • Enzo Biochem Inc • Services-medical laboratories • Delaware
Avista Healthcare Public Acquisition Corp. has requested that portions of this document be accorded confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. SETTLEMENT AND LICENSE AGREEMENT Confidential materials omitted...Settlement and License Agreement • October 9th, 2018 • Avista Healthcare Public Acquisition Corp. • Pharmaceutical preparations • Delaware
This Settlement and License Agreement (“Agreement”) is effective as of the date it is last signed (“Effective Date”), including the releases attached to it as Exhibit B and Exhibit C, by each of the following (each a “Party” and collectively, the “Parties”):
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • November 7th, 2014 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is made and effective as of September ___, 2014 (the “Effective Date”), by and between, on the one hand, Sucampo AG and Sucampo Pharmaceuticals, Inc. (collectively, “Sucampo”), R-Tech Ueno, Ltd. (“RTU”), Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals America, Inc. (collectively, “Takeda”), and on the other hand, Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc. (collectively, “Par”). Sucampo, RTU, Takeda, and Par are collectively referred to as the “Parties,” and each separately as a “Party.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • April 7th, 2006 • LML Payment Systems Inc • Services-business services, nec • Delaware
THIS SETTLEMENT AND PATENT CROSS-LICENSE AGREEMENT (the “Settlement and License Agreement”) is entered on April 3, 2006 (the “Effective Date”) by and among LML Patent Corp., a Delaware corporation having its principal place of business at Corporation Trust Centre, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware, 19801, LML Payment Systems, Inc., a Canadian entity with its principal place of business at 1140 West Pender Street, Suite 1680, Vancouver, British Columbia, Canada V6E4G1 and LML Payment Systems Corp., a Delaware corporation with its principal place of business at 1330 RiverBend Drive, Suite 600, Dallas, Texas 75247 (collectively “LML”), and TeleCheck Services, Inc. and TeleCheck International, Inc., both Delaware corporations having their principal place of business at 5251 Westheimer Road, Houston, Texas 77056 (collectively “TeleCheck”) and First Data Corp., a Delaware corporation with its principal place of business at 6200 South Quebec Street, Greenw
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • June 8th, 2016 • Enzo Biochem Inc • Services-medical laboratories • Delaware
This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is made and entered into as of May 16, 2016 (the “Effective Date”) by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 (“Enzo”), and Defendant Life Technologies Corporation, a corporation organized and existing under the laws of the State of Delaware, having offices at 5791 Van Allen Way, Carlsbad, California, 92008 (“Life”). Enzo and Life are individually referred to herein as a “Party,” and collectively as the “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • July 19th, 2012 • Somaxon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
The Court, upon the consent and request of Plaintiffs Somaxon Pharmaceuticals, Inc. and ProCom One, Inc. (collectively, “Plaintiffs”) and Defendants Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively “Par”), hereby Finds:
RECITALSSettlement and License Agreement • December 13th, 2004 • Corixa Corp • Biological products, (no disgnostic substances) • California
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • September 27th, 2021
This SETTLEMENT AND LICENSE AGREEMENT (together with all Exhibits attached hereto, the “Agreement”), is made and entered into as of May 14, 2010 (the “Effective Date”), by and among Microsoft Corporation, a Washington corporation (Microsoft Corporation together with its Affiliates, “Microsoft”), on the one hand, and VirnetX Inc., a Delaware corporation (VirnetX Inc. together with its Affiliates, “VirnetX”), on the other hand. As used herein, “Party” refers to any of VirnetX or Microsoft individually, and “Parties” refers to VirnetX and Microsoft collectively.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • April 29th, 2005 • Rambus Inc • Semiconductors & related devices • Delaware
THIS SETTLEMENT AND LICENSE AGREEMENT (the “Agreement”) is made by and among Rambus Inc. (“Rambus”), on the one hand, and Infineon Technologies AG, Infineon Technologies North America Corp. and Infineon Technologies Holding North America Inc. (collectively, “Infineon”), on the other hand, effective as of March 18, 2005 (“Effective Date”).
Settlement and License AgreementSettlement and License Agreement • November 13th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New Jersey
This Settlement and License Agreement (“Agreement”), effective April 12, 2017, is entered into by and between BioMarin Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 770 Lindaro Street, San Rafael, California 94901 (“BioMarin”), Merck & Cie, a Swiss corporation having a principal place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“Merck”) (together “Plaintiffs”); and Par Pharmaceutical, Inc. (“Par”), a company organized under the laws of Delaware, having a principal place of business at 300 Tice Boulevard, Woodcliff Lake, NJ 07677. Each of BioMarin, Merck, and Par are individually referred to herein by name or the term “Party” and collectively referred to herein as “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • June 14th, 2004 • Intellisync Corp • Services-prepackaged software • California
This Settlement and License Agreement (this “Agreement”) is made and entered into effective as of the 3rd day of March, 2004 (the “Effective Date”), by and between Intellisync Corp., a Delaware corporation (“Intellisync”), and Extended Systems Incorporated, a Delaware corporation (“ESI”) (each a “party” and collectively the “parties”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • February 11th, 2011 • Cephalon Inc • Pharmaceutical preparations • Delaware
This Settlement and License Agreement (the “Agreement”) is entered into this 7th day of October, 2010 (the “Agreement Date”), by and between Anesta AG and Eurand, Inc., each on their own behalf and on behalf of their Affiliates, and Impax Laboratories, Inc., on its own behalf and on behalf of its Affiliates.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • April 19th, 2022 • Alvotech Lux Holdings S.A.S. • Biological products, (no disgnostic substances) • Delaware
THIS SETTLEMENT AND LICENSE AGREEMENT (“Agreement”), effective April 4, 2022 (“Effective Date”), is entered into by and among AbbVie Biotechnology Ltd on behalf of itself and its Affiliates, a corporation organized and existing under the laws of Bermuda with a place of business at Harbour Fiduciary Services Limited, Thistle House, 4 Burnaby Street, Hamilton Pembroke HM 11, Bermuda (including its Affiliates “AbbVie”); and Alvotech hf., a corporation organized and existing under the laws of the Republic of Iceland, with its corporate headquarters at Saemundargata 15-19, 101 Reykjavik, Iceland (collectively and including their Affiliates “Alvotech”).
CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT ASTERISKS (*) DENOTE SUCH OMISSIONS SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • March 13th, 2006 • Monolithic Power Systems Inc • Semiconductors & related devices • California
This Settlement and License Agreement (the “Agreement”) is made and effective the 1st day of October, 2005, by and between Linear Technology Corporation, with offices at 1630 McCarthy Blvd., Milpitas, CA 95035 (“Linear”) and Monolithic Power Systems, Inc., with offices at 983 University Avenue, Building A, Los Gatos, CA 95032 (“MPS”). Linear and MPS are collectively referred to as the “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • August 7th, 2009 • Warner Chilcott LTD • Pharmaceutical preparations • New York
This is an agreement (hereinafter referred to as “Agreement”) dated as of this 9th day of January, 2009, by and among Warner Chilcott Company, Inc. (“WCCI”), a corporation organized and existing under the laws of Puerto Rico, and Watson Pharmaceuticals, Inc. (“WPI”), a corporation organized and existing under the laws of the State of Nevada, and Watson Laboratories, Inc. (“WLI”, and, together with WPI, “Watson”), a corporation organized and existing under the laws of the State of Nevada. WCCI and Watson are sometimes individually referred to herein as a “Party” and collectively referred to herein as “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • May 15th, 2015 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is hereby entered into and made effective on February 13, 2015 (the “Effective Date”) by and between Cephalon, Inc. (“Cephalon”) and Eagle Pharmaceuticals, Inc. (“Eagle”). Cephalon and Eagle are referred to herein individually as a “Party” and collectively, as the “Parties.”
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • January 24th, 2008 • Ariba Inc • Services-prepackaged software • Massachusetts
This Settlement and License Agreement (this “Agreement”), effective as of the date when executed by all Parties hereto and the signatory to Exhibit C (the “Effective Date”), is made and entered into between Sky Technologies, LLC, a Massachusetts limited liability company, Ariba, Inc., a Delaware corporation, and Procuri, Inc. (each a “Party” and collectively the “Parties”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • June 20th, 2012 • LML Payment Systems Inc • Services-business services, nec • New York
This Settlement and License Agreement (“Agreement”) is entered into as of March 5, 2012 (the “Effective Date”) by and between LML Patent Corp., a corporation organized under the laws of Delaware (“Plaintiff”), and JPMorgan Chase Bank, N.A. , a national association with a principal place of business at 270 Park Avenue, New York, NY 10017 (“Defendant”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • August 9th, 2010 • VirnetX Holding Corp • Patent owners & lessors • Texas
This SETTLEMENT AND LICENSE AGREEMENT (together with all Exhibits attached hereto, the “Agreement”), is made and entered into as of May 14, 2010 (the “Effective Date”), by and among Microsoft Corporation, a Washington corporation (Microsoft Corporation together with its Affiliates, “Microsoft”), on the one hand, and VirnetX Inc., a Delaware corporation (VirnetX Inc. together with its Affiliates, “VirnetX”), on the other hand. As used herein, “Party” refers to any of VirnetX or Microsoft individually, and “Parties” refers to VirnetX and Microsoft collectively.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • August 8th, 2008 • Sepracor Inc /De/ • Pharmaceutical preparations • Massachusetts
This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and effective as of April 30, 2008 (the "Effective Date"), by and between Sepracor Inc., a Delaware corporation having its principal place of business at 84 Waterford Drive, Marlborough, MA 10752 ("Sepracor"), and Breath Limited, a United Kingdom corporation having its registered address at 930 High Road, London, N12 9RT, United Kingdom ("Breath Limited") (each a "Party" and collectively, the "Parties").
Settlement and License AgreementSettlement and License Agreement • August 2nd, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New Jersey
This Settlement and License Agreement (“Agreement”), effective April 12, 2017, is entered into by and between BioMarin Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 770 Lindaro Street, San Rafael, California 94901 (“BioMarin”), Merck & Cie, a Swiss corporation having a principal place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“Merck”) (together “Plaintiffs”); and Par Pharmaceutical, Inc. (“Par”), a company organized under the laws of Delaware, having a principal place of business at 300 Tice Boulevard, Woodcliff Lake, NJ 07677. Each of BioMarin, Merck, and Par are individually referred to herein by name or the term “Party” and collectively referred to herein as “Parties.”
